The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Stand Up to Cancer and Boston College publish nursing training modules in immunotherapy

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

STAND UP TO CANCER published a series of Certification for Nursing Education training modules, with the Boston College William F. Connell School of Nursing, focused on immunotherapy.

The first web-based CNE modules will be available in July. In its first round, the program will seek to train 25 nurses working in immunotherapy. The program was announced as part of National Nurses Week, May 6-12.

The program will address providing care for cancer patients receiving immunotherapy, including education on immunology and related pathophysiology, symptom management, and nursing interventions to reduce symptom distress and promote wellness. The modules will meet CNE standards and each module will provide 3.5 to 5 contact hours from the Boston College William F. Connell School of Nursing.

Table of Contents

YOU MAY BE INTERESTED IN

Clinical

Oncofertility coverage mandates expand to 21 states and DC as political momentum builds
Gaps persist as patients face harrowing decisions and huge copays

The nagging pain in Mia Sandino’s right knee set in in September 2018, and throughout her freshman year at the University of Washington, she tried to ignore it. “I was being a very naive and invincible-feeling 19-year-old,” Sandino told The Cancer Letter. “I didn’t put two and two together that this area of the knee that...

By Claire Marie Porter and Sara Willa Ernst
Guest Editorial

My introduction to, and lessons learned from, Rick Pazdur

Rick Pazdur, MD, the newly appointed director for the Center for Drug Evaluation and Research at the FDA, has been described as “greyhound thin” as a result of his dedication to cycling and lifting weights in the gym each day and, for a long time, a vegetarian diet. I first met him when he was the director of the Office of Oncology Drug Products (ODP) within CDER, in 2009.
By Mikkael A. Sekeres
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account